Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.69 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6095338 | 1.00 | TSHR (0.69) | TSHRTP53EGLN1EGLN3CA5A | |
| Maleic Acid SCHEMBL11860272 | 1.00 | TSHR (0.69) | TSHRTP53EGLN1EGLN3CA5A | |
| Maleic Acid SCHEMBL11768683 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL7551164 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL9813915 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Maleic Acid SCHEMBL9813908 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL18224111 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL16914549 | 0.96 | TSHR (0.64) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL5509708 | 0.93 | TSHR (0.60) | TSHRTP53EGLN1EGLN3CA5A | |
| Fumaric Acid SCHEMBL15055651 | 0.93 | TSHR (0.60) | TSHRTP53EGLN1EGLN3CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108101883-B | It is a kind of to be used to prevent drug of diabetic retinopathy and preparation method thereof | 佳木斯大学附属第医院 | 2018-11-13 | — | — | CN | disclosed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | disclosed |
| EP-1315729-A4 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PRODUTOS QUIMICOS E (BR) | 2004-07-07 | — | — | EP | disclosed |
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PACHECO, OGARI (BR) | 2004-06-03 | — | — | US | disclosed |
| EP-1315729-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristalia Produtos Quimicos e Farmaceuticos Ltda (BR) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002012241-A1 | COMPOUNDS IN THE FORM OF HOMODIMERIC, HETERODIMERIC AND/OR HOMO AND HETEROMULTIMERIC PRO-DRUGS; PROCESS FOR OBTAINING THESE PRO-DRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASIS-MEDIATED DISEASES OR DYSFUNCTION | Cristália Produtos Químicos e Farmacêuticos Ltda. (BR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106629-A1 | Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction | PEPD, PREP, PAPSS1 | KMT2A 4493/4885MEN1 1239/4885TSHR 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.